CTLA4 and neoplasm: Higher tumor TIDE prediction scores were associated not only with poor efficacy of immune checkpoint inhibition therapy but also with poor survival of patients treated with anti-PD1 and anti-CTLA4 (Zarogoulidis et al., 2013).